Candel Therapeutics 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good. All right. I am Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and glad to have with us as part of the next session, the CEO of Candel Therapeutics, Paul Peter Tak. We are just going to have kind of a casual discussion here. If anyone has a question, feel free to raise your hand. Paul Peter, thanks for your participation. Not sure if you want to start off with any opening statements before we jump into Q&A.
Good morning, everybody. Well, first, thanks for having me. We are in a very interesting phase of the company. I just came back from SITC, the immuno-oncology meeting, where we had three abstracts that we presented. One of them was a late-breaking abstract based on the PrTK05 study. We may come back to that. We had new data also in non-small cell lung cancer, where we used a proteomics approach. It was actually awarded the top 150 abstract award. Then we had another abstract about linoserpaturev, our second investigational medicine, which is also very interesting, that we tested probably the most difficult to treat form of cancer, recurrent glioblastoma, where we could show new immunological biomarker data. Then we are starting to see a subset of patients that live much longer than you would expect, even in recurrent glioblastoma. The prognosis is extremely unfavorable. A lot going on. We are very busy also.
It is a very strong focus on execution, right? That is in a nutshell some of the recent ideas.
Yeah. Let us jump into aglatimagene for localized prostate cancer.
Maybe we can just start off with the PrTK05 data.
Yeah You just presented at SITC.
I know the mechanism of this drug is pretty unique. I know that trial was intended to do some immune profiling, some biodistribution, some shedding. What can you say about the data that emerged out of that study, specifically on the immune profiling side, and how that kind of strengthens your confidence that this drug is acting in kind of like that multimodal mechanistic way that you believe it to be?
Yeah. The PrTK05 is an experimental medicine phase IIa clinical trial that was requested by the FDA. The question was really to repeat the old work on biodistribution and shedding. In other words, you test in different body compartments over time whether you can still detect the viral gene construct. We had shown in the past that it's all gone within a few months, which you would expect because it's replication defective adenovirus, it cannot replicate. Second, the cells that we infect, we kill actually by giving valacyclovir, right? The FDA requested, and rightly so I think, to repeat that experiment with more state-of-the-art technology, and it's one figure on the poster that we presented last week at SITC, where we basically reproduced these findings. Then I thought, well, we're going to inject aglatimagene into the prostate of patients with localized intermediate-risk prostate cancer.
Let's use this actually to take some extra samples to do sophisticated immunological biomarker research, because the biosamples were not available from the phase III clinical trial that delivered on the clinical endpoints supported by secondary and exploratory endpoints. But we wanted to measure the systemic immune activation after localized delivery of prostate cancer, which is important for multiple reasons. Let's first focus on the findings.
The key findings included a very clear increase in the number of circulating CD8-positive T cells, including CD8-positive, granzyme B-positive, that means they are cytotoxic, Ki67-positive, that means they are proliferating T cells in the blood. Also a clear increase in the number of effector memory cells and central memory cells, which may explain the durable responses that we've seen after aglatimagene injection. So, it supports the notion that aglatimagene is a systemic immunotherapy that is delivered locally. We've shown exactly the same already in the past in other solid tumors like glioblastoma. So we used to have a program for aglatimagene in glioblastoma as well as part of first-line treatment.
We discontinued that for portfolio prioritization reasons, but actually we had very interesting data that we published in Neuro-Oncology that we could show that after aglatimagene delivered to the brain, we see a broadening of the T cell receptor repertoire associated with improved survival. We also had data at SITC a few days ago that we showed the same in non-small cell lung cancer, where we did proteomics, and where we also have shown a broadening of this T cell receptor repertoire, which is explained by the fact that we basically educated T cells to recognize a whole variety of cancer antigens and cancer neoantigens that are specific for the patient's own tumor.
Call participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
